Login
$ZYBT
$1.53 +$0.10 (6.99%) Pre-market

Consolidated Balance Sheets

In millions of CNY, except per-share amounts
Q4 FY2025
As of Dec 31, 2025
Q4 FY2024
As of Dec 31, 2024
Current assets:
Cash
Restricted cash
Short-term investments
Notes receivable, net
Accounts receivable, net
Advance to suppliers
Inventories, net
Other receivables, net
Prepayments and other current assets, net
Other receivable-a related party
Total current assets
Non-current assets:
Property, plant and equipment, net
Land use rights, net
Intangible assets, net
Right-of-use assets, net
Long-term prepayments
Deferred IPO expenses
Net deferred tax assets
Total non-current assets
Total assets
Current liabilities:
Short-term loans
Current maturities of long-term loans
Operating lease liability-current
Accounts payable
Contract liabilities
Taxes payable
Amount due to related parties
Accrued expenses and other liabilities
Total current liabilities
Non-current liabilities:
Long-term loans
Operating lease liability-non-current
Deferred tax liabilities
Total non-current liabilities
Total liabilities
Shareholders’ equity:
Ordinary shares, value
Class A ordinary shares
Class B ordinary shares
Total ordinary shares, value
Additional paid-in capital
Statutory reserves
Retained earnings (deficit)
Accumulated other comprehensive income
Total Zhengye Biotechnology Holding Limited’s shareholders’ equity
Noncontrolling interests
Total equity
Total liabilities and equity

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support